Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study

Pathology and Oncology Research

Volumn 21, Issue 4, 2015, Pages 1027-1035

  Záveský, Luděk ^a   Jandáková, Eva ^b   Turyna, Radovan ^c   Langmeierová, Lucie ^a   Weinberger, Vít ^b   Záveská Drábková, Lenka ^d,e   Hůlková, Martina ^a   Hořínek, Aleš ^a   Dušková, Daniela ^a   Feyereisl, Jaroslav ^c   Minář, Luboš ^b   Kohoutová, Milada ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c INSTITUTE FOR THE CARE OF MOTHER AND CHILD   (Czech Republic)

^d INSTITUTE OF MATHEMATICS   (Czech Republic)

^e INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Endometrial cancer; microRNA; miR 106b; miR 92a; Ovarian cancer; Urine

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 100; MICRORNA 106B; MICRORNA 1228; MICRORNA 16; MICRORNA 200B; MICRORNA 20A; MICRORNA 21; MICRORNA 223; MICRORNA 29A; MICRORNA 367; MICRORNA 92A; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; ENDOMETRIUM CANCER; EXOSOME; FEMALE; GENE EXPRESSION; GYNECOLOGIC SURGERY; HUMAN; INTERMETHOD COMPARISON; MIDDLE AGED; OVARY CANCER; PILOT STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SUPERNATANT; UPREGULATION; URINALYSIS; VERY ELDERLY; CASE CONTROL STUDY; ENDOMETRIAL NEOPLASMS; GENETICS; OVARIAN NEOPLASMS; PROGNOSIS; URINE;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; EXOSOMES; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; OVARIAN NEOPLASMS; PILOT PROJECTS; PROGNOSIS; UP-REGULATION;

EID: 84940448066     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-015-9914-y     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. Ca-Cancer J Clin 64:9–29. doi:10.3322/caac.21208
2. Howlader N, Noone AM, Krapcho M et al. (eds) (2013) SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD. [http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013].
3. Zavesky L, Jancarkova N, Kohoutova M (2011) Ovarian cancer: origin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease. Neoplasma 58:457–468. doi:10.4149/neo_2011_06_457
4. Devor EJ, Hovey AM, Goodheart MJ et al (2011) microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep 26:995–1002. doi:10.3892/or.2011.1372
5. Banno K, Nogami Y, Kisu I et al (2013) Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer. Int J Mol Sci 14(6):12123–12137. doi:10.3390/ijms140612123
6. Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159. doi:10.1002/emmm.201100209
7. Zhao YN, Chen GS, Hong SJ (2014) Circulating MicroRNAs in gynecological malignancies: from detection to prediction. Exp Hematol Oncol 3:14. doi:10.1186/2162-3619-3-14
8. Weber JA, Baxter DH, Zhang SL et al (2010) The MicroRNA Spectrum in 12 Body Fluids. Clin Chem (Washington, DC, U S) 56:1733–1741. doi:10.1373/clinchem.2010.147405
9. Yamada Y, Enokida H, Kojima S et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529. doi:10.1111/j.1349-7006.2010.01816.x
10. Bryant RJ, Pawlowski T, Catto JWF et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. doi:10.1038/bjc.2011.595
11. Mengual L, Loyano JJ, Ingelmo-Torres M et al (2013) Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 133(11):2631–2641. doi:10.1002/ijc.28274
12. Hanke M, Hoefig K, Merz H et al (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol Semin Orig Invest 28:655–661. doi:10.1016/j.urolonc.2009.01.027
13. Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y (2014) Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 5(3):182–191. doi:10.7150/jca.6799
14. Wang G, Chan ESY, Kwan BCH et al (2012) Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10(2):106–113. doi:10.1016/j.clgc.2012.01.001
15. Zhao S, Fernald RD (2005) Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 12:1047–1064. doi:10.1089/cmb.2005.12.1047
16. Guescini M, Sisti D, Rocchi MBL et al (2008) A new real-time PCR method to overcome significant quantitative inaccuracy due to slight amplification inhibition. BMC Bioinf 9:326. doi:10.1186/1471-2105-9-326
17. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper - excel-based tool using pair-wise correlations. Biotechnol Lett 26:509–515. doi:10.1023/B:BILE.0000019559.84305.47
18. Andersen CL, Jensen JL, Ørntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250. doi:10.1158/0008-5472.CAN-04-0496
19. Wyman SK, Parkin RK, Mitchell PS et al (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. Plos One 4:e5311. doi:10.1371/journal.pone.0005311
20. Resnick KE, Alder H, Hagan JP et al (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112:55–59. doi:10.1016/j.ygyno.2008.08.036
21. Dahiya N, Sherman-Baust CA, Wang TL et al (2008) MicroRNA expression and identification of putative miRNA targets in ovarian cancer. Plos One 3(6):e2436. doi:10.1371/journal.pone.0002436
22. Hausler SFM, Keller A, Chandran PA et al (2010) Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 103:693–700. doi:10.1038/sj.bjc.6605833
23. Shapira I, Oswald M, Lovecchio J et al (2014) Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer 110:976–983. doi:10.1038/bjc.2013.795
24. Laios A, O’Toole S, Flavin R et al (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7:35. doi:10.1186/1476-4598-7-35
25. Dong P, Kaneuchi M, Watari H et al (2014) MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog 53:349–359. doi:10.1002/mc.21983
26. Ni X, Xia T, Zhao T et al (2014) Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci 105:18–25. doi:10.1111/cas.12309
27. Hiroki E, Akahira J, Suzuki F et al (2010) Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101:241–249. doi:10.1111/j.1349-7006.2009.01385.x
28. Kan CWS, Hahn MA, Gard GB et al (2012) Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12:627. doi:10.1186/1471-2407-12-627